This program offers financial support of up to €55,000 for laureates, along with tailored support throughout the project lifecycle. This support includes project setup and monitoring, technology transfer assistance, help in finding further funding (regional, national, or European), and project promotion. It also fosters networking within the PUI ecosystem.
Eligible participants are research units and health institutions within the PUI, provided the project is led by a PUI member in collaboration with a private partner (an existing company or a startup project). The aid allocated to research units ranges from €10,000 excl. VAT to €50,000 excl. VAT. An additional €5,000 is available for projects involving the recruitment of at least one intern.
The program's progression involves several stages: a preliminary link between the laboratory and the private partner, application dossier preparation, evaluation and defense before the PUI committee, project launch, and finally, partnership support and sustainability.
Application deadlines for upcoming sessions are set for January 11, 2027, May 24, 2027, and November 2, 2027. Results will be announced in March 2027 and July 2027.
Since its inception, Companies and Campus has supported 156 innovative projects, funded 77 projects, and invested €3,436,541. Partners have raised over €8 million upon program completion, initiated 27 partnerships, and signed more than 10 exploitation licenses.
The list of 2026 laureates includes diverse projects such as the development of plant-based lipid vesicles (pVLsCos), exploration of new therapeutic perspectives for inflammation control (IMPACT), and the creation of biodegradable 3D implants (3D-KBONE).
The 2025 laureates cover areas like innovative therapies for chronic diseases (GREATUB), validation of a new therapeutic tool for cystic fibrosis (STABCFTR), and the study of gene involvement in rare pain conditions (MAD).
In 2024, laureate projects focus on the design of new intraocular lenses (CRISTEST), identification of pathogenic viruses (IEIV), synthesis of linotrines (SENALINORINF), and development of innovations for microscopes (3D-4-Pedia).
The 2023 laureates include projects on developing a therapeutic bacterium for Alzheimer's (NEUROBIOMICS), valorizing wood waste (RECOMPOSE), and new theranostic tools for multiple myeloma (PRECISIONMEDMM).
The 2021 laureate projects concern areas such as neuroprotection in Alzheimer's disease (FENM-AD), mangrove monitoring (GOLUM), and insulin therapy management via a mobile app (PHARE).
In 2020, supported projects address effluent depollution ecotechnology (Water EcoCase), agriculture in controlled environments (MYCINDOOR), and therapeutic solutions for rare diseases (Progeria).
The 2019 laureates are working on new marine biodiversity indicators (ADNe Indicateurs), theranostic tools for multiple myeloma (PRECISIONMEDMM), and sampling methods to estimate vineyard yield (PIC@).
The 2018 laureate projects include the construction of a surgical robot (RETINOCT), the development of a multispectral probe (SALSA), and the development of a new test on mesenchymal stem cells (ANOMALIES GENETIQUES).
